Abstract
The synthetic pentasaccharide (1) corresponding to the heparin sequence which binds to, and activates, antithrombin III (AT III) is a potent antithrombotic compound in several animal models of venous thrombosis. We describe here the preparation and the pharmacological properties of 34, an analogue of oligosaccharide 1 with the latter's N-sulfates being replaced by sulfate esters and hydroxyl groups being methylated. These structural modifications allow a simpler and more efficient synthesis of such anionic oligosaccharides. Affinity for human AT III, anti-factor Xa activity, ability to inhibit thrombin generation, antithrombotic activity in a rat model of venous thrombosis, and elimination half-life in the rat have been determined for 1 and 34. Surprisingly, introduction of O-sulfates in place of N-sulfates, and methylation of hydroxyl groups, contributes to reinforce the binding to AT III, resulting in an improved pharmacological profile.
References
Mar 1, 1977·Thrombosis Research·A N Teien, M Lie
Jun 1, 1989·Thrombosis Research·G M VogelP M Hobbelen
Oct 6, 1987·Biochemistry·S KoizumiT Nagatsu
Apr 15, 1987·Thrombosis Research·J M WalengaJ Choay
Sep 15, 1987·Carbohydrate Research·M PetitouG Torri
Feb 1, 1981·Thrombosis Research·E J McKay
Oct 31, 1983·Biochemical and Biophysical Research Communications·J ChoayG Gatti
Nov 1, 1994·Bioorganic & Medicinal Chemistry·P WesterduinD G Meuleman
Jan 1, 1994·Seminars in Thrombosis and Hemostasis·S T Olson, I Björk
Citations
Aug 31, 1999·Carbohydrate Research·P DuchaussoyJ M Herbert
Aug 22, 2001·Trends in Biotechnology·S J Williams, G J Davies
May 27, 2003·Biochimie·Eugen SisuPierre Sinay
May 18, 1999·Bioorganic & Medicinal Chemistry Letters·M PetitouJ M Herbert
Nov 13, 2001·Reviews in Clinical and Experimental Hematology·A GreinacherV Kiefel
Feb 11, 2005·European Journal of Clinical Investigation·S Alban
Feb 3, 2007·Chemical & Pharmaceutical Bulletin·Fumihiko SaitohIchiro Yamamoto
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Perumal Thiagarajan
Nov 13, 2008·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Stephanie K A BlickLesley J Scott
Sep 11, 2001·Biochemical and Biophysical Research Communications·N C KaneiderC J Wiedermann
Apr 10, 2015·Thrombosis and Haemostasis·Salvatore Andrea MastroliaOffer Erez
Jan 28, 2010·American Journal of Surgery·Sandra BattistelliTommaso Gori
Aug 2, 2001·American Heart Journal·A G Turpie
Jul 26, 2005·Chemistry & Biology·Christian Noti, Peter H Seeberger
Feb 6, 2015·PeerJ·Michela QuarantaGershon Holcberg
Oct 30, 2016·Thrombosis and Haemostasis·Salvatore Andrea MastroliaOffer Erez
Feb 24, 2001·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·A N DaudJ Fareed
Jan 6, 2004·Medicinal Research Reviews·Umesh R Desai
Apr 14, 1999·Nature·M PetitouJ M Herbert
Aug 9, 2003·Blood·Alec MushunjeJames A Huntington
Mar 2, 2011·Journal of Molecular Recognition : JMR·Helena C CastroCarlos R Rodrigues
Mar 18, 2000·The Journal of Biological Chemistry·K J BelzarJ A Huntington
Apr 22, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Stephanie K A BlickLesley J Scott
Apr 6, 2001·Chemistry : a European Journal·M PetitouJ M Herbert
Jul 6, 2004·Drugs·Neil A ReynoldsLesley J Scott
Jan 5, 2002·Chemistry : a European Journal·S K DasP Sinaÿ
Mar 8, 2002·Journal of Medicinal Chemistry·Gunnar T Gunnarsson, Umesh R Desai
May 3, 2014·Journal of Medicinal Chemistry·Sucharita RoyGanesh V Kaundinya